Introduction
Ischemia is a leading cause of acute renal failure (ARF), but it is also an unavoidable step in renal transplantation. Ischemic renal failure is usually followed by recovery of renal function. However, experimental studies have shown that recovery is incomplete when acute injury is severe. 1 Moreover, ARF after ischemia/reperfusion in the context of renal transplantation predisposes the graft to developing chronic damage and to long-term graft loss. 2, 3 In the early phase of kidney transplantation, when the transplanted kidney is exposed to insults as ischemia/ reperfusion (I/R) or nephrotoxic doses of immunosuppressant, hepatocyte growth factor (HGF) protects against acute renal injury and may enhance regeneration. [4] [5] [6] HGF is a multifactorial cytokine. It has been suggested that it is the long-searched-for renotropin that supports the intrinsic ability of the kidney to regenerate in response to injury. 7, 8 HGF has multiple activities in a wide range of cells including morphogenic, 9 mitogenic, 10 motogenic 11 and antiapoptotic 12 functions, and has shown its therapeutic properties in a variety of pathological conditions such as tissue regeneration, tissue fibrosis and dysfunction under chronic disease conditions. [12] [13] [14] However, exogenous HGF is extremely unstable in blood circulation: it has a half-life of 3-5 min 15 making it almost impossible to reach optimal blood levels. Gene therapy appears to be the alternative that can avoid this half-life handicap.
Gene therapy is now moving from experimental studies to clinical applications, [16] [17] [18] but gene transfer methodology is one of the limiting steps. Viral vector gene transfer has proved efficient but does not allow repetitive injection. In addition, though administration of naked plasmid DNA or liposome-formulated DNA is feasible, the levels of the therapeutic protein obtained are too low. However, DNA electrotransfer has greatly improved nonviral gene transfer efficiency. In vivo muscle electroporation has shown that consistently high levels of gene expression could be achieved for many genes. 19 This gene therapy methodology is free from oncogenicity, cytotoxicity and immunogenicity of the viral vectors 20 and improves the transgene expression after plasmid suspension injection, by two or three orders of magnitude. To develop more specific and homogenous organ-targeted gene therapy, direct gene delivery to organ is currently being assayed. [21] [22] [23] In the present study, we examine whether human HGF (hHGF) gene electrotransfer helps in the recovery from ARF in a model of rat renal warm ischemia. We also assess the advantages of this new form of gene therapy by direct electroporation of the kidney, given that transplantation offers the possibility of manipulating the organ in vivo.
The aim of this study was to compare the therapeutic efficiency of two electroporation methodologies in a rat model of ARF, which, although they both targeted the same organ, were applied to different parts of the animal: muscle and kidney.
Results

Preliminary studies
We assayed three electroporation voltages to optimize the kidney electroporation protocol. We chose 100 V/cm because it was the highest voltage that had no harmful early macroscopic effects on renal tissue. We further followed this group for 1 week and found no abnormality in renal function or in histological studies (data not shown).
Human HGF plasma levels and expression of human HGF in renal tissue
To test the efficiency of gene therapy methodology, hHGF protein plasma levels were determined on day 7 after ischemia (10th day after electroporation) in all groups (see Figure 1c) . Moreover, the time course kinetics of hHGF in plasma was assessed in ISCH (ischemic nontreated) and ISCH+KIDNEP (ischemic hHGF-electroporated kidney) groups ( Figure 1d ). As expected, hHGF was not detected in the ISCH group. ISCH+KIDNEP showed a considerable increase in hHGF levels on the 3rd day postelectroporation (just before ischemia) and reached the highest plasma levels on the 6th day, maintaining them until the end of the study. At that time point, ISCH+MUSCEP also promoted synthesis of hHGF protein in plasma, but not as much as ISCH+ KIDNEP did. Plasma hHGF levels in ISCH+MUSCEP group on the 10th day are comparable to those previously reported by our group. 24 As observed (Figure 1a and b) hHGF was expressed in the cytoplasm of the epithelial tubular cells in a granular pattern. All kidneys of the ISCH+KIDNEP group showed positive immunostaining (Figure 1b) , even though it was in a parcellar distribution. Only three of the six kidneys of ISCH+MUSCEP (ischemic kidney, hHGF muscle electroporated) rats were hHGF positive, while ISCH group did not show any tubular staining in any section.
Expression of rat HGF and rat TGF-b1 in renal tissue
To evaluate whether exogenous hHGF affects the endogenous expression of rat HGF (rHGF), a ratspecific enzyme-linked immunosorbent assay was performed.
On the 7th day after ischemia rats were killed and kidneys processed to determine rHGF and rTGF-b1 in renal tissue. These were also assessed in nonischemic kidneys used as controls (SHAM), to establish basal levels.
rHGF protein levels in renal tissue (Table 1) were significantly higher in ISCH+KIDNEP and ISCH+ MUSCEP than in the ISCH group, which values were also significantly higher than those of SHAM. Although no differences were observed in rTGF-b tissue levels, the ratio between the two values was significantly lower in ISCH+KIDNEP (Figure 2 ). To assess whether injected hHGF affected the recovery of renal function after 45 min of warm ischemia and contralateral nephrectomy, blood creatinine levels were measured on days 1, 3, 5 and 7 after injury ( Figure 3 ). Both treated groups showed lower creatinine levels than ischemic nontreated ones did soon after ischemic injury ( 
Analysis and quantification of necrotic and apoptotic cell death
To evaluate HGF structural protection against renal injury, we first examined the effect of HGF electrotransfer on tubular cell death.
The ISCH group showed the characteristic severe features of acute tubular necrosis. The tubular necrosis score was lower in both HGF-treated groups, but only significantly so in the ISCH+KIDNEP group in relation to the ISCH animals ( Table 2 ). The tubular necrosis score of ISCH+KIDNEP group was clearly lower than ISCH+ MUSCEP group.
For apoptosis, Apoptag s immunostaining revealed clear differences between both the treated groups and the nontreated group (Table 2) . Control nontreated kidneys showed a wide range in the number of apoptotic tubular epithelial cells, corresponding to their interindividual resistance to ischemia. Contrarily, HGF-treated animals had more homogeneous and well-preserved kidney tissues ( Figure 4 ). For a more complete analysis, apoptosis was also assessed with anti-PARP p85 fragment immunostaining, showing similar results to Apoptag technique, as depicted in Figure 4 .
Cell proliferation and regeneration
The proliferating effects of hHGF gene therapy on kidney after I/R insult were measured in two ways. First, as described in the methodology, conventional histologies were analyzed and tissues were blind-determined from 0 to 3. These results showed more mitotic cells in both treated groups than in the nontreated one ( Figure 5 ). Second, tissue PCNA was measured by real-time PCR, showing a large amount of this antigen in the ISCH+ KIDNEP group compared to the ISCH one. 
Inflammatory cell infiltration
To evaluate postischemic inflammatory cell response, macrophage and T/B lymphocytes were quantified by ED1 and CD45RC immunohistochemistry. Moreover, polymorphonuclear presence was determined by MPO quantification. hHGF-treated groups had fewer macrophages and lymphocytes than the nontreated ischemic group (Table 3) 
Discussion
This study demonstrated the protective effect of HGF gene therapy on ARF induced by renal warm ischemia. Two methods of HGF gene electrotransfer were compared. First, a distant source of circulating hHGF in skeletal muscle was created by electroporation targeting the kidney and other organs. Second, the same electrotherapy was used directly on the kidney.
Electrotransfer is a classic technique used in in vitro studies that has recently been adapted to experimental in vivo gene therapy and it is normally applied after intramuscular injection. [25] [26] [27] The original contribution of this paper is the direct gene therapy electroporation of the targeted organ. As few authors have recently employed electroporation on different kinds of organs with success, [20] [21] [22] [23] we decided to electroporate the kidney directly. In the preliminary study, we confirmed the absence of tissue and functional damage after kidney electroporation. This was important, since no therapeutic strategy that implies any kind of injury to a healthy kidney that might compromise its subsequent function is acceptable. Muscle-and kidney-electroporated animals produced similar levels of plasma hHGF, so both electroporation protocols are comparable in terms of efficiency. Probably kidney, like muscle, 24 is a source of hHGF, in that cells, when efficiently transfected with the plasmid, are converted into hHGF protein producers. We 25 and other authors 28 showed previously that exogenous hHGF induces endogenous production of rHGF. In the present study, both hHGF-treated groups not only showed high levels of plasma hHGF but increased endogenous rHGF levels, corroborating that gene hHGF electrotransfer clearly increases rat renal HGF production. It is questionable whether the increase in rHGF is directly induced by ischemia. 29 In fact, although we demonstrate this ischemic-induced physiological response, we also show supraphysiological rHGF production in the treated groups. Serum and kidney hHGF expression confirmed that the gene was efficiently transfected, and rHGF in renal tissue proved the effective induction of the endogenous protein in the target organ. The values reported in this work are much higher than those reported by other authors that in fact showed heterogeneous levels of rat and human HGF in both renal tissue and serum. [30] [31] [32] [33] [34] Interestingly, even though endogenous rHGF levels of both treatments are similar, the renal rTGF-b1/rHGF ratio is significantly lower in ISCH+KIDNEP, demonstrating the well-known antagonistic effect of HGF and TGF-b1. 35 The different ratios of the two treated groups summarize the different efficiency of each therapy, since, as has been described, 36, 37 an increase in TGF-b1 or a decrease in local HGF expression may be responsible for renal fibrosis and tubular destruction. Why the renal rTGF-b1/rHGF ratio is lower when the plasmid is locally injected into the kidney is a matter of debate. A probable explanation is the proximity between therapeutic agent producer cells (renal cells converted into autocrine or paracrine secretors) and those ischemia-insulted cells lacking the therapy.
ARF occurs with a fall of renal function (for hours or a few days) acute tubular necrosis (combined apoptosis and cell desquamation), and inflammation (cellular infiltration). With hHGF electrotransfer, these symptoms are ameliorated. The recovery in both treated groups was much better than in ischemic nontreated kidneys, but it was especially clear when therapy was directly applied into the kidney. This was for two main reasons. First, early postischemic creatinine levels never reached the high levels of the nontreated group. Moreover, from the first day, the kidney-treated group showed a more pronounced recovery of the renal function, changing the typical creatinine profile displayed by the other two groups.
This earlier functional recovery is parallel to the significant amelioration observed in the histological study, in which those treated with HGF were much better preserved from ischemic insult: less tubular apoptosis and necrosis along with greater cellular regeneration. Note that there was clearly less tubular cell necrosis with the direct kidney approach than with the distant intramuscular approach. As it has been demonstrated, the HGF antiapoptotic effect aids early renal recovery, since less I/R-induced apoptosis prevents the development of inflammation and organ dysfunction. 38 Even though ischemia-induced HGF is physiologically synthesized as a natural repair process, its overexpression induced by gene therapy supports cytoprotective actions through that antiapoptotic effect. As our results show, this gene therapy reduced apoptotic cells: the only apoptotic cells were tubular cells. As described, 35 in HGF-treated animals, endogenous rHGF may induce the expression of antiapoptotic proteins such as Bcl-2 and Bcl-xl and may also inactivate the proapoptotic Bad protein. Both lead to reduced cell apoptosis. Related to the anti-apoptotic effect is that prosurvival properties of HGF are corroborated in treated groups by slightly higher levels of PCNA corresponding to increased tubular epithelial regenerative cells.
In a model of inflammatory bowel disease, 39 HGF showed anti-inflammatory effects through the decrease of the expression of TNF-a and IFN-g, suggesting that HGF may work directly or indirectly to reduce these inflammatory mediators. Moreover, in vitro, the suppression of TNF-a-induced E-selectine expression has been shown. 40 In our study, the antiinflammatory effect of HGF was not clearly expressed, although we observed the tendency in both treated groups. There are two possible explanations for this. First, ischemic nontreated kidneys varied greatly in almost all parameters studied, including inflammation. Second, since the inflammatory response to I/R injury peaks 3-10 days after injury, 41, 42 there is no guarantee that the 7th day after I/R is the optimal moment when inflammation is fully expressed.
For a long time, attempts to reduce the deleterious effects induced by ischemic insult have had varied success. The aim of this study was to compare the efficacy of two electroporation methodologies. Although they both targeted the same organ, the two methods were applied to different parts of the animal: muscle and kidney. Although intramuscular HGF gene electrotransfer appears to be a promising therapy, kidney direct electrotransfer was shown to be more efficient not only in pharmacokinetic but also in therapeutic terms, so it may become a clinically practical alternative in renal transplantation. Two different applications of that therapy can be set: muscle electroporation in native kidney pathologies, applied as soon as they are detected, and kidney electroporation ex vivo at the moment of organ harvesting in renal transplantation.
Materials and methods
Plasmid construction
The hHGF expression vector used in the present study was constructed and optimized as previously described by our group. 24 In that study, we reported an efficient hHGF direct kidney electrotransfer M Franquesa et al gene therapy approach formulating plasmid DNA with the nonionic carrier SP1017 (Supratek-Pharma, Laval, Canada), and demonstrating it to be more efficient than naked DNA electroporation. Briefly, the hHGF cDNA was excised from the pBluescript-SK by digestion with SalI and SacI and cloned at the same restriction sites of the pSP72 (Promega). A Flag sequence from the pCMVtag4 was introduced into the SalI site of the pSP72. Finally, hHGFflag sequence was removed from pSP72hHGFflag by NotI digestion and subcloned into the pCIneo plasmid. The resultant vector was named pCMV/hHGF. Plasmids were expanded into the Escherichia coli strain JM-109 and purified using the EndoFree plasmid Giga kit (Qiagen GmbH, Hilden, Germany). DNA was dissolved in Endofree TE buffer at a concentration of 4 mg/ml.
Equal volumes of plasmid DNA and SP1017 (0.02%) were gently mixed to a final DNA concentration of 2 mg/ml and 0.01% wt/vol of SP1017.
Animals and in vivo electroporation
Recommendations for the proper care and use of laboratory animals were followed.
Animals were divided into three groups: ISCH: 45 min of warm ischemia and no pretreatment (n ¼ 8); ISCH+ MUSCEP. hHGF muscle injection and subsequent electroporation, 3 days before 45 min of renal warm ischemia (n ¼ 8); and ISCH+KIDNEP: renal artery injection of hHGF and kidney electroporation 3 days before 45 min of renal warm ischemia (n ¼ 11).
Electroporation was performed 3 days before ischemia because, in previous intramuscular studies, 24 hHGF plasma levels peaked between 3 and 5 days after gene electrotransfer.
All rats were Sprague-Dawley weighing between 250-300 mg and were anesthetized i.p. by a combination containing ketamine (30 mg/kg), atropine (0.25 mg/kg) and diazepam (0.625 mg/kg).
Muscle electroporation. Legs were shaved and moistened with 70% ethanol. Plasmid was injected into the tibialis anterior muscle by a 28-gauge needle in a proximal to distal direction inside the tissue. The injected volume was 200 ml per leg. Following the intramuscular injection of plasmid DNA, an electrical field was applied to the area around the injection. Muscles were held by caliper electrodes composed of two 1.5 cm 2 steel plates, and electric pulses were delivered to the muscle by pulse generator (BTX ECM830 electroporator Genetronics Inc., San Diego, CA, USA). Eight pulses of 20 ms each at a frequency of 2 Hz were delivered with a voltage of 175 V/cm (optimized recently in our group). A conductive gel on the shaved leg ensured electrical contact with the skin. To improve plasmid DNA diffusion, 25 U of bovine hyaluronidase (Sigma) in 60 ml saline was injected into the muscle 2 h before the administration of plasmid DNA and the electroporation. 43 Kidney electroporation. Left kidney and pedicle were surgically exposed with a midline abdominal incision and the renal artery was clamped proximal to the aorta. We injected 400 ml of plasmid containing hHGF with a sterile insulin syringe (100-U). Immediately, the renal pedicle was clamped in order to avoid the leak of liquid, and an electric field was applied to the kidney, held with a tweezers-type electrode (same mechanism as in muscle). Then, the renal artery was sutured with a 9/0 filament and unclamped in less than 12 min (to avoid ischemic damage). In preliminary studies, three electroporation voltages (75, 100 and 125 V/cm) were assayed and 100 V/cm was applied to all kidneys: six pulses of 50 ms each at a frequency of 1 Hz, following the protocol of Tsujie. 20 Ischemia. 3 days after electrotransfer, animals were anesthetized as described above and the left kidney was surgically exposed with a midline laparotomy. The renal artery and vein were clamped in block to induce kidney ischemia for 45 min, during which animals were kept at 371C and a contralateral nephrectomy was carried out. Then, clamps were released and the animals were housed for a week. On days 1, 3, 5 and 7 the animals were weighed and blood obtained from tail vein, used for measuring creatinine levels (mmol/l) by Jaffe's reaction on an autoanalyzer (Beckman Instruments, Palo Alto, CA, USA). Kidneys were processed for histological and molecular studies on day 7 after ischemia.
Determination of human plasma HGF
Blood samples were collected in EDTA tubes, centrifuged at 900 g for 30 min at 41C and kept in polypropylene vials. The amount of human plasma HGF was measured using a commercially available ELISA kit (Quantikine KitTM, Research & Diagnostics Systems, Minneapolis, USA). Blood samples of kidney-electroporated animals of days 1, 3, 5 and 7 after ischemia were used to create a kinetic profile of expression.
Determination of renal TGF-b1 levels
Renal tissue was homogenized in 10 mM Tris-HCl buffered solution (pH 7.4) containing 2 M NaCl, 1 mM PMSF, 1 mM EDTA and 0.01% Tween 80. The samples were centrifuged at 19 000 g for 30 min, an aliquot of the supernatant was taken and the supernatant was stored at À801C till analysis. After homogenization, total protein concentration was measured by the Bradford protein assay (Bio-Rad, Hercules, CA, USA). TGF-b1 levels in tissue homogenate supernatants were measured in a 96-well microplate in a commercially available assay ELISA kit (Quantikine KitTM, Research & Diagnostics Systems, Minneapolis, USA). The levels of TGF-b1 in kidneys were expressed as ng/mg total protein.
Determination of rat kidney HGF
For measurements of tissue HGF level, tissue was homogenized in HGF extraction buffer containing 20 mM Tris-HCl, pH 7.5, 2 M NaCl, 0.1% Tween-80, 1 mM EDTA and 1 mM PMSF, as described previously. 44 The homogenates were centrifuged at 19 000 g for 30 min at 41C, and the supernatant was recovered for HGF quantification and total protein concentration. HGF was determined by a commercially available ELISA kit (Rat HGF EIA, Institute of Immunology, Tokyo, Japan). Total protein concentration was measured by Bradford's method (Bio-Rad); tissue HGF concentration was expressed in ng/mg protein.
This rHGF antibody does not crossreact with hHGF. 28 hHGF direct kidney electrotransfer M Franquesa et al
Histological studies
For light microscopy, 3-4 mm thick tissue sections were placed in 4% formaldehyde for paraffin embedding and subsequent staining with hematoxylin-eosin and periodic acid-Schiff (PAS). A score from 0 to 3 was given for each tubular profile of necrosis and regeneration by a pathologist who was blind to the material: 0, normal histology; 1, less than 1/3 of the specimen affected; 2, 1/3 to 2/3 of tissue injured; and 3, the whole section damaged. Tubular injury was assessed by cellular swelling and lysis, luminal cast formation, loss of cellular adhesion and brush border loss. Tubular regeneration was defined by the presence of nuclear mitosis.
Immunohistochemical analyses
Representative tissue sections were immunostained by the immunoperoxidase technique (Normal serum Horse 3:100 diluted, ABC 1:100, Vector Laboratories, Burlingame, CA, USA) as described. 45 As primary antibodies, we used a 1:100 diluted monoclonal mouse antirat antibody for ED-1 macrophages (Oxford Biomarketing, Oxford, UK), 1:200 diluted mouse monoclonal antirat antibody for leukocyte T and B protein CD45RC (Serotec, Oxford, UK) and 1:25 diluted goat polyclonal antihuman HGF antibody. As secondary antibodies, we used horse antimouse IgG (1:200; kit of Pierce Biotechnologies, Rockford, USA) and a horse antigoat IgG (1:200;Vector Laboratories, Burlingame, CA, USA). They were revealed using DAB (Sigma-Aldrich, St Louis, USA).
Apoptotic cells were stained using the Apoptag peroxidase kit (Labclinics, Barcelona, Spain) with a 50% diluted primary antibody and revealed with DAB, and by antiPARP p85 Fragment pAb (Promega, Madison, USA) 1:50 diluted and with an antirabbit IgG (1:200; Vectastain ABC kit; Vector Laboratories). Positive ED1 and Cd45Rc-stained and apoptotic cells in kidneys were counted and expressed as mean7s.e.m. of cells per field of view (+cells/FV, Â 40, X20 counted fields/kidney). PARP staining was analyzed by a blinded pathologist from 0 to 3 as explained above.
Quantification of renal HGF and PCNA by real-time PCR
RNA extraction and reverse transcription were performed in a total volume of 40 ml, as previously described. 45 Tissue cDNA proliferating cell nuclear antigen (PCNA) was amplified and quantified by realtime PCR (ABI Prism s 7700, Applied Biosystems, Spain), using the comparative C T (threshold cycle) method. We validated the method for our pair of amplicons (rat PCNA and rat rRNA 18S) (results not shown), so that the comparative C T method could be used. For rat 18S PCR reaction, 1 ml of each cDNA sample was mixed with 2 Â TaqMan s Universal PCR Master Mix (12.5 ml)+20 Â target primers and Probe (1.25 ml) in a total reaction volume of 25 ml. For rat PCNA PCR reaction, 1 ml of each cDNA sample was mixed with primers and probe in a total reaction volume of 25 ml to reach a final concentration of 900 nM for both forward and reverse primers and 200 nM for the probe. Amplification followed the universal amplification program proposed by Applied Biosystems and previously described. 45 Values of normal kidneys were pooled and used as the reference value.
Results were expressed as 'many fold of the unknown sample' with respect to the sham group values.
Tissue myeloperoxidase assay
Neutrophil infiltration in rat kidneys was assessed by measuring the activity of the neutrophil-specific MPO. A modification of Bradley's kinetic method, previously described in our group, was used. 46 Frozen tissue (0.1-0.2 g) was homogenized in 50 mM potassium phosphate buffer (pH 6.0) containing 0.5% hexadecyltrimethylammonium bromide. It was subsequently snap-frozen in liquid nitrogen and thawed in three consecutive steps and then underwent 30 s sonication, and a final 2 h incubation at 601C. After centrifugation, the supernatant was collected for MPO measurement. The assay consisted of determining the rate at which the colored product was formed during the MPO-dependent reaction of 0.167 mg/ml o-dianisidine and 0.0005% hydrogen peroxide, measured at 460 nm in spectrophotometer (Beckman). One unit of MPO activity was defined as that which degrades 1 mmol of peroxide/min at 251C. The MPO activity values are the mean levels after duplicate determinations and are expressed as a change in OD per minute per gram of tissue.
Statistical analysis
The StatView s 5 program (SAS Institute Inc.) was used for the statistical analysis. Quantitative data were compared using ANOVA followed by the Scheffe test. To compare groups for serum creatinine throughout the follow-up, this was compacted and compared by ANOVA for repeated measures. For histological data, the nonparametric Kruskall-Wallis test and then Connover's test were used. All P-values were two-tailed, with o0.05 taken as statistically significant. Data are shown as mean7s.e.m.
